[en] Whole-body metabolic information provided by 18F-FDG PET could help in the evaluation of lymphoma patients at diagnosis and follow-up. We studied 60 patients, 42 at initial presentation and 18 for disease recurrence (23 aggressive non-Hodgkin's lymphoma, 21 low-grade non-Hodgkin's lymphoma and 16 Hodgkin's disease). All patients underwent a clinical examination, computed tomography (CT) and a non-attenuated PET scan within 1 week. The patients received 222-296 MBq (6-8 mCi) 18F-FDG intravenously and emission scans were recorded 45-90 min later. 18F-FDG PET detected more lymph nodes than the clinical examination or CT, but this rarely resulted in upstaging (two patients). The concordance between PET and CT for the evaluation of the spleen, liver and digestive tract was quite good. Discordance was noted in 12 patients for the evaluation of bone marrow infiltration, but confirmation by MRI or focal biopsy was not always obtained. We conclude that non-attenuated 18F-FDG PET is an easy and efficient whole-body method for the evaluation of patients with lymphomas. Compared with conventional techniques, however, it does not appear to offer much improvement for staging but provides a satisfactory base for follow-up.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Warland, V.
Najjar, F.
Paulus, P.
Fassotte, M. F.
Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Language :
English
Title :
Whole-Body 18f-Fdg Pet for the Evaluation of Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma
Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, ed. Metabolism of tumors. London: Constable, 1930: 254-270.
Weber G. Enzymology of cancer cells. New Engl J Med 1977; 296: 486-551.
Wahl RL. Positron emission tomography: Application in oncology. In Murray ICP, Ell PJ, eds. Nuclear medicine, clinical diagnosis and treatment. London: Churchill Livingstone, 1995: 801-820.
Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
Conti PS, Lilien DL, Hawley K., et al. PET and (18F)-FDG in oncology: A clinical update. Nucl Med Biol 1996; 23: 717-735.
Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111-116.
Moog F, Bangerter M, Diederichs CG et al. Lymphoma: Role of whole-body 2-deoxy-2-(F-18) fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 302: 795-800.
Huh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 1997; 38: 343-348.
Schönberger JA, Stollfuss JC, Kocher F. Whole-body 18-FDG-PET for staging of malignant lymphomas. Eur J Nucl Med 1994; 21: 727.
Lapela M, Leskinen S, Minn HRI et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
Leskinen-Kallio S, Ruot Salainen U, Nagren K., et al. Uptake of carbon-II-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: A PET study. J Nucl Med 1991; 32: 1211-1218.
Rodriguez M, Rehn S, Ahlström H et al. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med 1995; 36: 1790-1796.
Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
de Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (suppl. I): S57-S60.
Okada J, Oonishi H, Yoshikawa K et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
Price P, Jones T, on behalf of the EC PET Oncology Concerted Action and the EORTC PET Study Group. Can positron emission tomography be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A: 1924-1927.
Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin’s disease. Cancer 1990; 65: 1090-1096.
Anderson KC, Leonard RCF, Canellos GP et al. High-dose gallium imaging in lymphoma. Am J Med 1993; 75: 327-331.
Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: Spectrum of disease. Radiographics 1991; 11: 647-669.
Barrington SF, Saunders CAD, Madan R et al. Can FDG-PET predict bone marrow involvement in patients with lymphoma? J Nucl Med 1997; 38 (suppl.): 128P.
Karp JS, Muehllehner G, Qu H, Yan XH. Singles transmission in volume-imaging PET with a 137Cs source. Phys Med Biol 1995; 40: 929-944.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body FDG-PET post-treatment evaluation in Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) has higher diagnostic and prognostic value than classical CT-scan imaging. Blood 1997; 90: 336a.
Jerusalem G, Beguin Y, Fassotte MF et al. Early assessment of response to chemotherapy by FDG-PET is highly predictive of outcome in patients with high-grade non-Hodg-kin’s lymphoma (NHL). Blood 1997; 90: 388a.
